Rapid Pathogen Screening, Inc. (RPS) and NicOx S.A. (NYSE Euronext Paris: COX) have announced the execution of worldwide licensing rights providing NicOx with exclusive access to RPS’s point-of-care tests in the field of ocular disease. The agreement covers three tests, AdenoPlus, currently authorised for marketing in the US and EU and two further tests currently in development. AdenoPlus identifies patients with adenoviral conjunctivitis in a point-of-care setting in which a tear sample provides sufficient material for a definitive result in less than ten minutes. The additional diagnostic tests under development are for the combined detection of adenoviral and allergic conjunctivitis and a third test for the detection of herpes.
Rapid Pathogen Screening Inc., licenses innovative diagnostic ophthalmic tests to NicOx S.A.
- by swdadmin